细胞穿透胜肽市场机会、成长驱动因素、产业趋势分析与预测 2024 - 2032

Cell Penetrating Peptide Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年10月17日 | 出版商:

Global Market Insights Inc. | 英文 139 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023 年，全球细胞穿透胜肽市场估值为19 亿美元，预计2024 年至2032 年复合年增长率将强劲增长12.9%。成长，如CPP具有将治疗剂直接输送到细胞的独特能力。透过增强药物、蛋白质和遗传物质向特定细胞标靶的输送，CPP 可以提高治疗效果，同时最大限度地减少潜在的副作用，这使得它们对于精准医疗特别有价值。细胞穿透胜肽是短链胺基酸，通常有 5 到 30 个残基，可以有效地穿过细胞膜。这些胜肽促进多种生物分子的细胞内递送，包括蛋白质、核酸和小型治疗化合物，而不会对细胞造成显着伤害。

它们采用多种细胞进入机制，包括胞吞作用和直接易位，这导致了对其在药物传输、基因治疗和各种生物医学领域的应用的广泛研究。 CPP 市场可依类型分为合成胜肽、蛋白质衍生胜肽和嵌合胜肽。 2023年，合成材料领域引领市场，占8.809亿美元。与天然或蛋白质衍生的对应物相比，合成 CPP 具有卓越的稳定性，可以更好地控制尺寸、电荷和疏水性等特性。

这种设计灵活性使它们非常适合各种药物传输应用，特别是在具有挑战性的生理条件下。在考虑应用时，药物传输领域在 2023 年占据最大的市场份额，达到 30.7%。 CPP 在将治疗药物直接递送至指定细胞或组织方面特别有效，可提高治疗精确度，同时减少脱靶效应。这种能力对于需要标靶治疗的疾病特别有益，因为它可以显着改善治疗结果并减少毒性。

市场范围
开始年份	2023年
预测年份	2024-2032
起始值	19亿美元
预测值	57 亿美元
复合年增长率	12.9%

北美将在2023 年成为最大的细胞穿透胜肽市场，产生7.37 亿美元的收入，预计到2032 年将达到21 亿美元。和应用递送和基因治疗。此外，对个人化医疗的大量投资以及基因编辑技术的进步，增加了对有效细胞内递送系统的需求，其中 CPP 有助于影响细胞屏障。

The Global Cell Penetrating Peptide Market was valued at USD 1.9 billion in 2023, with projections indicating a robust growth rate of 12.9% CAGR from 2024 to 2032. A key driver of this market expansion is the increasing demand for targeted drug delivery systems, as CPPs possess a unique capability to transport therapeutic agents directly into cells. By enhancing the delivery of drugs, proteins, and genetic materials to specific cellular targets, CPPs improve therapeutic effectiveness while minimizing potential side effects, making them particularly valuable for precision medicine. Cell-penetrating peptides are short chains of amino acids, typically ranging from 5 to 30 residues, that can effectively traverse cellular membranes. These peptides facilitate the intracellular delivery of a variety of biomolecules, including proteins, nucleic acids, and small therapeutic compounds, without causing significant harm to the cells.

They employ several mechanisms for cellular entry, including endocytosis and direct translocation, which has led to extensive research into their applications in drug delivery, gene therapy, and various biomedical fields. The market for CPPs can be categorized by type into synthetic, protein-derived, and chimeric peptides. In 2023, the synthetic segment led the market, accounting for USD 880.9 million. Synthetic CPPs provide superior stability compared to their natural or protein-derived counterparts, offering better control over properties such as size, charge, and hydrophobicity.

This design flexibility makes them well-suited for diverse drug delivery applications, particularly in challenging physiological conditions. When considering applications, the drug delivery sector held the largest market share in 2023, at 30.7%. CPPs are particularly effective in delivering therapeutic agents directly to designated cells or tissues, enhancing treatment precision while reducing off-target effects. This capability is especially beneficial for conditions requiring targeted therapies, as it can significantly improve treatment outcomes and reduce toxicity.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$1.9 Billion
Forecast Value	$5.7 Billion
CAGR	12.9%

North America emerged as the largest market for cell-penetrating peptides in 2023, generating USD 737 million in revenue and projected to reach USD 2.1 billion by 2032. The region's robust presence of biopharmaceutical firms and research organizations fuels the development and application of CPPs in drug delivery and gene therapy. Additionally, significant investments in personalized medicine, along with advancements in gene editing technologies, have heightened the demand for effective intracellular delivery systems, where CPPs help affect cellular barriers.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising demand for targeted drug delivery
  - 3.2.1.2 Advancements in biotechnology
  - 3.2.1.3 Technological innovations
  - 3.2.1.4 Increased focus on personalized medicine
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High production costs
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technology landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Protein-derived
5.3 Synthetic
5.4 Chimeric

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Drug delivery
6.3 Gene delivery
6.4 Diagnostics
6.5 Molecular imaging
6.6 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Pharmaceutical and biotechnology companies
7.3 Contract research organizations (CROs)
7.4 Hospitals and clinics
7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE